Pyramid Biosciences’ $864 Million Licensing Deal

Ballard Spahr advised Pyramid Biosciences on the deal.Clinical-stage biotechnology company Pyramid Biosciences, Inc. announced the development of a global licensing deal for two cancer therapies worth up…

This content is for members only.
Login to Read More Join Now
Martina Bellini

Author: Martina Bellini

This content is for members only.
Login to Read More Join Now